Agreement - January 4, 2026
Orexo in agreement with Dexcel to divest US rights to Zubsolv
The company has signed an agreement with Dexcel Pharma USA, to divest the full rights to Zubsolv (buprenorphine/naloxone) sublingual tablet CIII, for the treatment of opioid use disorder, in the US.
Biotech Business - January 2, 2026
MSD will not exercise its option for Evaxion’s Gonorrhea vaccine candidate
Consequently, Evaxion retains global rights to EVX-B2 and will look for another potential licensing partner.
Biotech Business - January 2, 2026
Alvotech announces European launch of first-in-market biosimilar to Simponi
Alvotech has announced that launches are underway in Europe for Gobivaz (golimumab), Alvotech’s biosimilar to Simponi (golimumab), also known as AVT05 (prefilled syringe and autoinjector).
MedTech Business - January 2, 2026
Episurf forms a new strategic business segment
The Board of Directors of Episurf Medical has entered into an agreement with Goldcup 38657 AB regarding the acquisition of all shares in Goldcup 38658 AB, a wholly owned subsidiary of the seller.
Clinical Trials - January 2, 2026
Hemab Therapeutics announces positive complete Phase 2 data
Hemab Therapeutics has announced positive results from its completed Phase 2 multiple ascending dose (MAD) portion of the CL-101 study of sutacimig for the prophylactic treatment of Glanzmann thrombasthenia (GT).
In a new job - January 2, 2026
Hedia appoints new CEO
Danish diabetes‑tech company Hedia is implementing a leadership change.
